Image courtesy of Mevion Medical Systems
November 20, 2015 – Mevion Medical Systems is announcing the Los Angeles Proton Center is building a three-room Mevion S250mx proton therapy system. The system will include Mevion’s Hyperscan pencil beam scanning technology and will be installed near Los Angeles, in the city of Montebello, on the campus of Beverly Hospital. The installation will take place in phases, with the first of the three rooms treating cancer patients in late 2017.
“The Mevion S250mx was the optimal solution for our facility because it allows for a flexible, phased installation,” said Charles Liu, president of the Los Angeles Proton Center. “Just as importantly, we continue to be impressed with the proven results of all of Mevion’s clinically operational systems, including Mevion’s industry-leading ramp-up time, high patient throughput, and low staffing and maintenance requirements. The decision to select Mevion and its product solutions will allow us to consistently provide high-quality proton therapy to a large number of patients.”
The Mevion S250mx is the fully scalable version of Mevion’s proton therapy technology and is available in two-, three- or four-room configurations. Each room is fully independent, with its own proton accelerator, providing inherent redundancy and 100 percent facility uptime 365 days per year.
The Los Angeles Proton Center is an independent proton center that will collaborate with renowned cancer specialists to treat adult and pediatric cancer patients from the Greater Los Angeles area. The center will also serve international patients who are seeking cancer care on the West Coast of the United States.
Similar Mevion systems have ramped up to full capacity in as little as three months and achieved an annualized rate of 350 patients per room, per year. That is more than 25 percent better than the average U.S. proton therapy center.
The Los Angeles system is the third system purchase announced by Mevion in the past six weeks. In October, Mevion announced the installation of a Mevion S250 to Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland, and a Mevion S250i with Hyperscan to the Ackerman Cancer Center in Jacksonville, Florida.
Hyperscan has not been cleared by the U.S. Food and Drug Administration for clinical use.
For more information: www.mevion.com